Patents Assigned to S-TARGET THERAPEUTICS GMBH
  • Immunoregulatory vaccine
    Patent number: 10434170
    Abstract: An immune-regulatory vaccine comprising—a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix, and—an immunogen with at least one epitope and a second peptidic alpha-helix coiled to the first alpha-helix, a kit for preparing the vaccine, and a sensibilizing vaccine comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a peptidic alpha-helix in a pharmaceutical formulation.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: October 8, 2019
    Assignee: S-TARGET THERAPEUTICS GMBH
    Inventor: Geert Mudde
  • Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
    Patent number: 10189905
    Abstract: A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.
    Type: Grant
    Filed: May 29, 2017
    Date of Patent: January 29, 2019
    Assignee: S-TARGET THERAPEUTICS GMBH
    Inventors: Geert Mudde, Gottfried Himmler
  • Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
    Patent number: 9636415
    Abstract: A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: May 2, 2017
    Assignee: S-TARGET THERAPEUTICS GMBH
    Inventors: Geert Mudde, Gottfried Himmler
  • IMMUNOREGULATORY VACCINE
    Publication number: 20150196636
    Abstract: An immune-regulatory vaccine comprising—a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix, and—an immunogen with at least one epitope and a second peptidic alpha-helix coiled to the first alpha-helix, a kit for preparing the vaccine, and a sensibilizing vaccine comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a peptidic alpha-helix in a pharmaceutical formulation.
    Type: Application
    Filed: July 2, 2013
    Publication date: July 16, 2015
    Applicant: S-TARGET THERAPEUTICS GMBH
    Inventor: Geert Mudde